Condition: Diabetes · IPMN, Pancreatic · PDAC - Pancreatic Ductal Adenocarcinoma · Sponsor: Fondazione Policlinico Universitario Campus Bio-Medico
LASERBLOOD is based on a biophotonic technology that can be used to predict the development of Pancreatic Ductal Adenocarcinoma (PDAC) in particular categories of subjects at risk (e.g. persons with diabetes, obese people, patients with Intraductal Papillary Mucinous Neoplasm \[IPMN\] or other cystic diseases of the pancreas, etc.) and at the same time offer the possibility of verifying the real effectiveness of the treatments to which affected patients are subjected.
This description comes directly from the study's public registry record.
Damiano Caputo, MD · +3906225418012 · d.caputo@policlinicocampus.it
Always discuss trial participation with your own doctor first.
| Fondazione Policlinico Universitario Campus Bio-Medico | Rome, Italy, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07659639